Clinical Trial Detail

NCT ID NCT02098967
Title A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia.
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

acute myeloid leukemia

Advanced Solid Tumor

Therapies

RO6839921

Age Groups: adult

No variant requirements are available.